These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 15650075)

  • 1. Species differences in the disposition of the CCR5 antagonist, UK-427,857, a new potential treatment for HIV.
    Walker DK; Abel S; Comby P; Muirhead GJ; Nedderman AN; Smith DA
    Drug Metab Dispos; 2005 Apr; 33(4):587-95. PubMed ID: 15650075
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preclinical pharmacokinetics and in vitro metabolism of dasatinib (BMS-354825): a potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL.
    Kamath AV; Wang J; Lee FY; Marathe PH
    Cancer Chemother Pharmacol; 2008 Mar; 61(3):365-76. PubMed ID: 17429625
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Disposition of the dipeptidyl peptidase 4 inhibitor sitagliptin in rats and dogs.
    Beconi MG; Reed JR; Teffera Y; Xia YQ; Kochansky CJ; Liu DQ; Xu S; Elmore CS; Ciccotto S; Hora DF; Stearns RA; Vincent SH
    Drug Metab Dispos; 2007 Apr; 35(4):525-32. PubMed ID: 17220241
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics and interactions of a novel antagonist of chemokine receptor 5 (CCR5) with ritonavir in rats and monkeys: role of CYP3A and P-glycoprotein.
    Kumar S; Kwei GY; Poon GK; Iliff SA; Wang Y; Chen Q; Franklin RB; Didolkar V; Wang RW; Yamazaki M; Chiu SH; Lin JH; Pearson PG; Baillie TA
    J Pharmacol Exp Ther; 2003 Mar; 304(3):1161-71. PubMed ID: 12604693
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity.
    Dorr P; Westby M; Dobbs S; Griffin P; Irvine B; Macartney M; Mori J; Rickett G; Smith-Burchnell C; Napier C; Webster R; Armour D; Price D; Stammen B; Wood A; Perros M
    Antimicrob Agents Chemother; 2005 Nov; 49(11):4721-32. PubMed ID: 16251317
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nonlinear oral pharmacokinetics of the alpha-antagonist 4-amino-5-(4-fluorophenyl)-6,7-dimethoxy-2-[4-(morpholinocarbonyl)-perhydro-1,4-diazepin-1-yl]quinoline in humans: use of preclinical data to rationalize clinical observations.
    Harrison A; Betts A; Fenner K; Beaumont K; Edgington A; Roffey S; Davis J; Comby P; Morgan P
    Drug Metab Dispos; 2004 Feb; 32(2):197-204. PubMed ID: 14744941
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preclinical pharmacokinetics and metabolism of 6-(4-(2,5-difluorophenyl)oxazol-5-yl)-3-isopropyl-[1,2,4]-triazolo[4,3-a]pyridine, a novel and selective p38alpha inhibitor: identification of an active metabolite in preclinical species and human liver microsomes.
    Kalgutkar AS; Hatch HL; Kosea F; Nguyen HT; Choo EF; McClure KF; Taylor TJ; Henne KR; Kuperman AV; Dombroski MA; Letavic MA
    Biopharm Drug Dispos; 2006 Nov; 27(8):371-86. PubMed ID: 16944451
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metabolism and disposition of the HIV-1 protease inhibitor ritonavir (ABT-538) in rats, dogs, and humans.
    Denissen JF; Grabowski BA; Johnson MK; Buko AM; Kempf DJ; Thomas SB; Surber BW
    Drug Metab Dispos; 1997 Apr; 25(4):489-501. PubMed ID: 9107549
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preclinical pharmacokinetics of a novel HIV-1 attachment inhibitor BMS-378806 and prediction of its human pharmacokinetics.
    Yang Z; Zadjura L; D'Arienzo C; Marino A; Santone K; Klunk L; Greene D; Lin PF; Colonno R; Wang T; Meanwell N; Hansel S
    Biopharm Drug Dispos; 2005 Dec; 26(9):387-402. PubMed ID: 16142720
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Species difference in the mechanism of nonlinear pharmacokinetics of E2074, a novel sodium channel inhibitor, in rats, dogs, and monkeys.
    Nagaya Y; Takenaka O; Kusano K; Yoshimura T
    Drug Metab Dispos; 2013 May; 41(5):1004-11. PubMed ID: 23401471
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative metabolism of 14C-labeled apixaban in mice, rats, rabbits, dogs, and humans.
    Zhang D; He K; Raghavan N; Wang L; Mitroka J; Maxwell BD; Knabb RM; Frost C; Schuster A; Hao F; Gu Z; Humphreys WG; Grossman SJ
    Drug Metab Dispos; 2009 Aug; 37(8):1738-48. PubMed ID: 19420130
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A pharmacokinetic-pharmacodynamic disease model to predict in vivo antiviral activity of maraviroc.
    Rosario MC; Jacqmin P; Dorr P; van der Ryst E; Hitchcock C
    Clin Pharmacol Ther; 2005 Nov; 78(5):508-19. PubMed ID: 16321617
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of NS-105, a novel cognition enhancer. 1st communication: absorption, metabolism and excretion in rats, dogs and monkeys after single administration of 14C-NS-105.
    Mukai H; Sugimoto T; Ago M; Morino A
    Arzneimittelforschung; 1999 Nov; 49(11):881-90. PubMed ID: 10604039
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics and disposition of the oxytocin receptor antagonist L-368,899 in rats and dogs.
    Thompson KL; Vincent SH; Miller RR; Colletti AE; Alvaro RF; Wallace MA; Feeney WP; Chiu SH
    Drug Metab Dispos; 1997 Oct; 25(10):1113-8. PubMed ID: 9321512
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics and disposition of L-692,429. A novel nonpeptidyl growth hormone secretagogue in preclinical species.
    Leung KH; Cohn DA; Miller RR; Doss GA; Stearns RA; Simpson RE; Feeney WP; Chiu SH
    Drug Metab Dispos; 1996 Jul; 24(7):753-60. PubMed ID: 8818572
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modipafant, a new PAF antagonist: pharmacokinetics and disposition in rat, dog and man.
    Jezequel SG; Uden S; Wastall P
    Xenobiotica; 1996 Sep; 26(9):963-75. PubMed ID: 8893043
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of tolterodine, a muscarinic receptor antagonist, in mouse, rat and dog. Interspecies relationship comparing with human pharmacokinetics.
    Påhlman I; Kankaanranta S; Palmér L
    Arzneimittelforschung; 2001 Feb; 51(2):134-44. PubMed ID: 11258043
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics and elucidation of the rates and routes of N-glucuronidation of PF-592379, an oral dopamine 3 agonist in rat, dog, and human.
    Attkins N; Betts A; Hepworth D; Heatherington AC
    Xenobiotica; 2010 Nov; 40(11):730-42. PubMed ID: 20836725
    [TBL] [Abstract][Full Text] [Related]  

  • 19. P-glycoprotein plays a role in the oral absorption of BMS-387032, a potent cyclin-dependent kinase 2 inhibitor, in rats.
    Kamath AV; Chong S; Chang M; Marathe PH
    Cancer Chemother Pharmacol; 2005 Feb; 55(2):110-6. PubMed ID: 15338193
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The disposition of voriconazole in mouse, rat, rabbit, guinea pig, dog, and human.
    Roffey SJ; Cole S; Comby P; Gibson D; Jezequel SG; Nedderman AN; Smith DA; Walker DK; Wood N
    Drug Metab Dispos; 2003 Jun; 31(6):731-41. PubMed ID: 12756205
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.